Case Report: Dynamic TKI Strategies for EGFR-Mutant NSCLC with Acquired ROS1 Fusion

A detailed clinical case report authored by Hua Yang, last updated June 4, 2026. It describes a single patient case of stage IV lung adenocarcinoma with brain metastasis, focusing on acquired resistance to EGFR inhibitors. The report details a treatment sequence spanning over 6.5 years from initial diagnosis.

Use Cases

• Analyzing treatment sequencing strategies based on the described use of osimertinib, crizotinib, entrectinib, and lorlatinib.
• Studying adverse event profiles and re-challenge tolerance based on the reported side effects of ROS1 inhibitors.
• Investigating rare resistance mechanisms based on the acquired ROS1 fusion bypass pathway described.

Strengths

• Report details a specific, rare clinical scenario with a documented survival of over 6.5 years.
• Provides a concrete timeline of sequential targeted therapies and their observed side effects.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is a single case report (18.7 KB), representing a limited scope.

Provenance

Source

Hua Yang via figshare

Collection Method

Clinical case documentation.

Time Range

Case timeline spans over 6.5 years from initial diagnosis.

Freshness

Last updated 2026-06-04 04:27:34; freshness should be verified.